^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IBI-343

    i
    Other names: IBI-343, IBI343
    Company:
    Innovent Biologics
    Drug class:
    Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    2ms
    Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Harbin Medical University
    New P2 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • IBI-343
    3ms
    G-HOPE-001: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P3 trial • Metastases
    |
    paclitaxel • irinotecan • IBI-343
    6ms
    Safety, tolerability and efficacy of IBI343 in combination with sintilimab in subjects with advanced gastric/gastro- Esophageal junction adenocarcinoma: A Phase II study (ChiCTR2300077564 )
    P2, N=25, Not yet recruiting, First Affiliated Hospital of Anhui Medical University
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • CLDN18.2 expression • CLDN18.2 positive
    |
    Tyvyt (sintilimab) • IBI-343
    over1year
    A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN18 (Claudin 18)
    |
    IBI-343
    almost2years
    A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=210, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    IBI-343